Nouvelles de la Bourse
Dernières actualités financières · Mis à jour Mai 23, 2026
Apple fête ses 50 ans : De la startup de garage à un géant de 3,73 billions de dollars — Combien valait un investissement de 1 000 $ à son introduction en bourse ?
Apple Turns 50: From Garage Startup To $3.73 Trillion Giant—Here's How Much A $1,000 Investment At Its IPO Would Be Worth Today
The panelists generally agreed that Apple's current valuation and future growth prospects are uncertain, with significant risks and opportunities ahead.
Je me suis demandé à quoi ChatGPT répondrait si je lui expliquais Ethereum comme à un enfant de 12 ans
I Asked ChatGPT To Explain Ethereum to Me Like I’m 12
The panel discussion on Ethereum's investment thesis highlights significant competition from other chains, regulatory risks, and the need for further …
Keir Starmalade, quelqu'un ? La marmelade devra-t-elle vraiment être renommée au Royaume-Uni ?
Keir Starmalade, anyone? Will marmalade really have to be rebranded in UK?
The panel generally agrees that the marmalade labeling change is a non-event for major UK food companies, with some long-term …
« Pas tout à fait Greggs » : les créateurs de TikTok testent les boulangeries « gentrifiées » de Londres
‘Not quite Greggs’: TikTok creators put London’s ‘gentrified’ bakeries to the test
The panel's net takeaway is that while these premium-priced, artisanal bakeries benefit from TikTok-driven visibility, their long-term resilience and profitability …
Goldman Sachs relève sa cible de prix sur PVH Corp. (PVH) à 93 $ contre 83 $
Goldman Sachs Raises its Price Target on PVH Corp. (PVH) to $93 from $83
The panelists had a mixed view on PVH's outlook, with some flagging risks like EMEA softness, reliance on margin expansion, …
Ascendis Pharma A/S (ASND) rapporte des données positives de la semaine 52 de l'essai de phase 2 New InsiGHTS
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial
The panel discusses ASND's Week 52 Phase 2 data showing TransCon hGH's non-inferiority to daily somatropin, with YUVIWEL's EMA approval …
Wolfe Research initie la couverture de BeOne Medicines AG (ONC) avec une note Outperform
Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform Rating
The panel is neutral on BeOne Medicines (ONC), with concerns about Brukinsa's long-term margins due to generic competition and uncertainty …
Mizuho abaisse son objectif de cours sur Autolus Therapeutics plc (AUTL) à 10 $ depuis 12 $
Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12
The panelists debated AUTL's outlook, with some highlighting its strong Q4 results and potential for 2026 inflection, while others raised …
Galapagos NV (GLPG) signe un accord avec Gilead sur les actifs d'Ouro Medicines
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
GLPG's partnership with Gilead on gamgertamig provides a pipeline extension and potential near-to-mid-term catalyst, but the deal's true value lies …
RBC Capital baisse son objectif de cours sur Bicycle Therapeutics plc (BCYC) à 7 $ contre 11 $
RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11
BCYC's one-time revenue from terminated partnerships masks a pivot away from zelenectide due to regulatory feedback, reducing near-term commercialization visibility. …
Les meilleurs FNB pour un pétrole à 100 $ à acheter dès maintenant
The Best ETFs For $100 Oil To Buy Right Now
The panel consensus is that while $105 WTI is driven by geopolitical risks, it may not be sustained due to …
TD Cowen relève son objectif de cours sur Marex Group plc (MRX) à 66 $ contre 61 $
TD Cowen Raises its Price Target on Marex Group plc (MRX) to $66 from $61
Panelists are divided on Marex Group (MRX). Bulls highlight record revenue beats and potential re-rating, while bears question the sustainability …